Fibrogen Inc   (FGEN)
Other Ticker:  


What are Fibrogen Inc's Business Segments?

Fibrogen Inc is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for serious unmet medical needs. The company focuses on three main segments of products and services, including:

1. Anemia and Fibrosis Treatment - Fibrogen's anemia and fibrosis products and services are developing groundbreaking therapies for anemia and conditions that lead to fibrosis. They work together to restore normal homeostasis to tissues and organ systems affected by these disorders. The company's lead anemia product is Roxadustat, an oral treatment for anemia of chronic kidney disease (CKD). Fibrogen is also developing a tissue-specific pan-TGF-beta inhibitor for advanced fibrosis.

2. Cancer Immunotherapy - Fibrogen is involved in developing a range of cancer immunotherapy products and services in collaboration with its partners. These therapies offer unique mechanisms of action designed to boost the immune system's ability to fight cancer. Fibrogen's leading cancer immunotherapy product is pamrevlumab, a monoclonal antibody currently under development for pancreatic cancer, gastric cancer, and other solid tumors.

3. Gene Therapy and Rare Diseases - Fibrogen aims to leverage its expertise in developing innovative therapies for complex diseases and expand into gene therapy and rare diseases segment, where it focuses on developing biologics for rare or orphan diseases with high unmet need. The company is developing ARA 290, which acts as a restorative molecule for rare diseases.

Overall, Fibrogen has a strong portfolio of products and services dedicated to helping patients with serious unmet medical needs. They continue to drive innovation in research and development to bring new treatments to market and improve patient outcomes.

Fibrogen Inc Tax Rate Companies within the Major Pharmaceutical Preparations Industry

Business Segments Q3
(in millions $)
(in millions $)
(Sep 30 2023)
(Profit Margin)
Total 40.13 -63.62 -

Growth rates by Segment Q3
Y/Y Revenue
(Sep 30 2023)
Q/Q Revenue
Y/Y Income
(Sep 30 2023)
Q/Q Income
Total 155.06 % -9.44 % - -

To get more information on Fibrogen Inc's Total segment. Select each division with the arrow.


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com